Weekly CEO News from Richard Ingram
October 1, 2018

At the last possible moment, Trump made a deal with Canada. NAFTA is gone USMCA is in but details lacking. Goodbye NAFTA. Hello USMCA. It’s the “single greatest agreement ever signed”. What did it do? There are two ways to

Read more

Healthcare was the best-performing sector of the third quarter, jumping 14.1% — its highest quarterly gain since the first quarter of 2013. The dual tailwinds of encouraging industry fundamentals and the sector’s defensive tilt led to the rally in the

Read more

Treasury yields went up across the curve throughout the third quarter of 2018. Once again the rate move was led by the front end of the yield curve, with Treasury bills and notes out to three years experiencing the largest

Read more

The chart below shows the performance of three U.S. housing stock indexes this year. They are all down YTD, with the Home Construction Index down the most (almost 25%). If the high in January is used as a reference level, then

Read more

The November natural gas contract shot higher today as traders appear increasingly concerned about low storage levels ahead of the impending winter season.    The whole winter strip shot higher on the day, but with far less buying from March

Read more

Although the financial press is all lathered up about the last minute trade agreement reached between the Americans and the Canadians, I am left asking, “what’s the big deal, eh?” Did we really expect anything different? Sure, Trump blustered about

Read more

In the rational world of textbook investing, investors should pay up for safety and be compensated for risk, but for the past 20 years, the opposite has been the case in US equity markets. As BofA’s Savita Subramanian notes, the market

Read more

TM Editors’ Note: This article discusses one or more stocks that are, or have recently been, penny stocks. Such stocks are easily manipulated; do your own careful due diligence. BiolineRx (BLRX) is slated to report on complete data at the

Read more

TM Editors’ Note: This article discusses one or more stocks that are, or have recently been, penny stocks. Such stocks are easily manipulated; do your own careful due diligence. BiolineRx (BLRX) is slated to report on complete data at the

Read more

Here is the latest update of a popular market valuation method using the most recent Standard & Poor’s “as reported” earnings and earnings estimates and the index monthly average of daily closes for the past month. For the earnings, see

Read more